Shanghai Fosun Pharmaceutical (Group) Co (HK:2196) has released an update.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has announced that its subsidiary, Yaopharma Co., Ltd., has received acceptance from the National Medical Products Administration for the registration of two new drugs, Sodium nitroprusside and Flurbiprofen axetil injections, aimed at treating various acute medical conditions. The company assures the information’s accuracy and accepts legal liability for the contents of the announcement. These new drugs are intended for critical care in hypertensive emergencies, acute heart failure, and providing postoperative and cancer pain relief.
For further insights into HK:2196 stock, check out TipRanks’ Stock Analysis page.